PTC Therapeutics, Inc. Research and Development Expense
PTC Therapeutics, Inc. (PTCT) reported Research and Development Expense of $99.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- PTC Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $99.15M, a 12.25% decline year-over-year.
- PTC Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $100.87M, a 7.43% decline year-over-year.
- PTC Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $133.13M, a 6.70% increase year-over-year.
- PTC Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $100.16M, a 37.95% decline year-over-year.
- PTC Therapeutics, Inc. research and development expense for fiscal 2025 was $455.25M, a 14.82% decline from fiscal 2024.
- PTC Therapeutics, Inc. research and development expense for fiscal 2024 was $534.48M, a 19.82% decline from fiscal 2023.
- PTC Therapeutics, Inc. research and development expense for fiscal 2023 was $666.56M, a 2.31% increase from fiscal 2022.
- PTC Therapeutics, Inc. research and development expense for fiscal 2022 was $651.50M, a 20.49% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $99.15M 10-Q · filed 2026-07-30 | $200.02M 10-Q · filed 2026-07-30 | $333.15M derived: sum of 3 quarters · filed 2026-07-30 | $433.31M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $100.87M 10-Q · filed 2026-05-07 | $234.00M derived: sum of 2 quarters · filed 2026-05-07 | $334.16M derived: sum of 3 quarters · filed 2026-05-07 | $447.15M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $133.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $233.29M derived: sum of 2 quarters · filed 2026-02-19 | $346.28M derived: sum of 3 quarters · filed 2026-07-30 | $455.25M 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | $100.16M 10-Q · filed 2025-11-04 | $213.15M derived: sum of 2 quarters · filed 2026-07-30 | $322.12M 10-Q · filed 2025-11-04 | $446.89M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $112.99M 10-Q · filed 2026-07-30 | $221.96M 10-Q · filed 2026-07-30 | $346.73M derived: sum of 3 quarters · filed 2026-07-30 | $508.14M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $108.97M 10-Q · filed 2026-05-07 | $233.74M derived: sum of 2 quarters · filed 2026-05-07 | $395.15M derived: sum of 3 quarters · filed 2026-05-07 | $527.32M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $124.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $286.18M derived: sum of 2 quarters · filed 2026-02-19 | $418.35M derived: sum of 3 quarters · filed 2026-02-19 | $534.48M 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | $161.41M 10-Q · filed 2025-11-04 | $293.58M derived: sum of 2 quarters · filed 2025-11-04 | $409.71M 10-Q · filed 2025-11-04 | $531.06M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | $132.17M 10-Q · filed 2025-08-07 | $248.30M 10-Q · filed 2025-08-07 | $369.65M derived: sum of 3 quarters · filed 2026-02-19 | $533.86M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | $116.13M 10-Q · filed 2025-05-06 | $237.48M derived: sum of 2 quarters · filed 2026-02-19 | $401.69M derived: sum of 3 quarters · filed 2026-02-19 | $587.57M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | $121.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $285.56M derived: sum of 2 quarters · filed 2026-02-19 | $471.44M derived: sum of 3 quarters · filed 2026-02-19 | $666.56M 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | $164.21M 10-Q · filed 2024-11-07 | $350.09M derived: sum of 2 quarters · filed 2024-11-07 | $545.21M 10-Q · filed 2024-11-07 | $733.90M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $185.87M 10-Q · filed 2024-08-08 | $381.00M 10-Q · filed 2024-08-08 | $569.69M derived: sum of 3 quarters · filed 2025-02-27 | $735.15M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $195.12M 10-Q · filed 2024-04-25 | $383.82M derived: sum of 2 quarters · filed 2025-02-27 | $549.28M derived: sum of 3 quarters · filed 2025-02-27 | $706.54M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $188.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $354.16M derived: sum of 2 quarters · filed 2025-02-27 | $511.42M derived: sum of 3 quarters · filed 2025-02-27 | $651.50M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $165.46M 10-Q · filed 2023-10-26 | $322.73M derived: sum of 2 quarters · filed 2023-10-26 | $462.80M 10-Q · filed 2023-10-26 | $612.65M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | $157.26M 10-Q · filed 2023-08-03 | $297.34M 10-Q · filed 2023-08-03 | $447.19M derived: sum of 3 quarters · filed 2024-02-29 | $578.03M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | $140.08M 10-Q · filed 2023-04-27 | $289.92M derived: sum of 2 quarters · filed 2024-02-29 | $420.77M derived: sum of 3 quarters · filed 2024-02-29 | $546.25M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | $149.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $280.69M derived: sum of 2 quarters · filed 2024-02-29 | $406.17M derived: sum of 3 quarters · filed 2024-02-29 | $540.68M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | $130.84M 10-Q · filed 2022-10-27 | $256.33M derived: sum of 2 quarters · filed 2022-10-27 | $390.84M 10-Q · filed 2022-10-27 | $508.85M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $125.48M 10-Q · filed 2022-08-04 | $260.00M 10-Q · filed 2022-08-04 | $378.01M derived: sum of 3 quarters · filed 2023-02-21 | $471.01M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-03-31 | $134.51M 10-Q · filed 2022-05-03 | $252.53M derived: sum of 2 quarters · filed 2023-02-21 | $345.52M derived: sum of 3 quarters · filed 2023-02-21 | $522.05M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2020-12-31 | $118.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $211.01M derived: sum of 2 quarters · filed 2023-02-21 | $387.54M derived: sum of 3 quarters · filed 2023-02-21 | $477.64M 10-K · filed 2023-02-21 | ||||
| 2020-09-30 | $93.00M 10-Q · filed 2021-10-28 | $269.52M derived: sum of 2 quarters · filed 2021-10-28 | $359.63M 10-Q · filed 2021-10-28 | $441.46M derived: sum of 4 quarters · filed 2022-02-22 | ||||
| 2020-06-30 | $176.53M 10-Q · filed 2021-07-29 | $266.63M 10-Q · filed 2021-07-29 | $348.46M derived: sum of 3 quarters · filed 2022-02-22 | $411.54M derived: sum of 4 quarters · filed 2022-02-22 | ||||
| 2020-03-31 | $90.11M 10-Q · filed 2021-05-04 | $171.94M derived: sum of 2 quarters · filed 2022-02-22 | $235.01M derived: sum of 3 quarters · filed 2022-02-22 | $294.99M derived: sum of 4 quarters · filed 2022-02-22 | ||||
| 2019-12-31 | $81.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $144.91M derived: sum of 2 quarters · filed 2022-02-22 | $204.89M derived: sum of 3 quarters · filed 2022-02-22 | $257.45M 10-K · filed 2022-02-22 | ||||
| 2019-09-30 | $63.08M 10-Q · filed 2020-10-29 | $123.06M derived: sum of 2 quarters · filed 2020-10-29 | $175.62M 10-Q · filed 2020-10-29 | $229.27M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $59.98M 10-Q · filed 2020-08-05 | $112.54M 10-Q · filed 2020-08-05 | $166.19M derived: sum of 3 quarters · filed 2021-02-25 | $220.56M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $52.57M 10-Q · filed 2020-04-30 | $106.21M derived: sum of 2 quarters · filed 2021-02-25 | $160.58M derived: sum of 3 quarters · filed 2021-02-25 | $193.19M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $53.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $108.02M derived: sum of 2 quarters · filed 2021-02-25 | $140.62M derived: sum of 3 quarters · filed 2021-02-25 | $171.98M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $54.37M 10-Q · filed 2019-10-30 | $86.97M derived: sum of 2 quarters · filed 2019-10-30 | $118.34M 10-Q · filed 2019-10-30 | $147.57M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $32.61M 10-Q · filed 2019-08-06 | $63.97M 10-Q · filed 2019-08-06 | $93.20M derived: sum of 3 quarters · filed 2020-03-02 | $123.23M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $31.36M 10-Q · filed 2019-05-02 | $60.60M derived: sum of 2 quarters · filed 2020-03-02 | $90.62M derived: sum of 3 quarters · filed 2020-03-02 | $121.46M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $29.23M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $59.26M derived: sum of 2 quarters · filed 2020-03-02 | $90.09M derived: sum of 3 quarters · filed 2020-03-02 | $117.46M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $30.02M 10-Q · filed 2018-11-05 | $60.86M derived: sum of 2 quarters · filed 2018-11-05 | $88.22M 10-Q · filed 2018-11-05 | $114.23M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $30.84M 10-Q · filed 2018-08-07 | $58.20M 10-Q · filed 2018-08-07 | $84.21M derived: sum of 3 quarters · filed 2019-03-01 | $115.61M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $27.36M 10-Q · filed 2018-05-09 | $53.37M derived: sum of 2 quarters · filed 2019-03-01 | $84.77M derived: sum of 3 quarters · filed 2019-03-01 | $113.60M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $26.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $57.41M derived: sum of 2 quarters · filed 2019-03-01 | $86.23M derived: sum of 3 quarters · filed 2019-03-01 | $117.63M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $31.40M 10-Q · filed 2017-11-02 | $60.22M derived: sum of 2 quarters · filed 2017-11-02 | $91.62M 10-Q · filed 2017-11-02 | $126.67M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-06-30 | $28.83M 10-Q · filed 2017-08-09 | $60.23M 10-Q · filed 2017-08-09 | $95.27M derived: sum of 3 quarters · filed 2018-03-06 | $125.91M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-03-31 | $31.40M 10-Q · filed 2017-05-08 | $66.45M derived: sum of 2 quarters · filed 2018-03-06 | $97.09M derived: sum of 3 quarters · filed 2018-03-06 | $125.28M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2015-12-31 | $35.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $65.69M derived: sum of 2 quarters · filed 2018-03-06 | $93.88M derived: sum of 3 quarters · filed 2018-03-06 | $121.82M 10-K · filed 2018-03-06 | ||||
| 2015-09-30 | $30.64M 10-Q · filed 2016-11-03 | $58.83M derived: sum of 2 quarters · filed 2016-11-03 | $86.77M 10-Q · filed 2016-11-03 | $113.64M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $28.19M 10-Q · filed 2016-08-04 | $56.13M 10-Q · filed 2016-08-04 | $83.00M derived: sum of 3 quarters · filed 2017-03-16 | $101.76M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | $27.94M 10-Q · filed 2016-05-05 | $54.81M derived: sum of 2 quarters · filed 2017-03-16 | $73.57M derived: sum of 3 quarters · filed 2017-03-16 | $91.89M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2014-12-31 | $26.87M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $45.64M derived: sum of 2 quarters · filed 2017-03-16 | $63.95M derived: sum of 3 quarters · filed 2017-03-16 | $79.84M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | $18.77M 10-Q · filed 2015-11-09 | $37.08M derived: sum of 2 quarters · filed 2015-11-09 | $52.97M 10-Q · filed 2015-11-09 | $67.99M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $18.31M 10-Q · filed 2015-07-31 | $34.20M 10-Q · filed 2015-07-31 | $49.22M derived: sum of 3 quarters · filed 2016-02-29 | $63.11M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $15.89M 10-Q · filed 2015-05-05 | $30.91M derived: sum of 2 quarters · filed 2016-02-29 | $44.80M derived: sum of 3 quarters · filed 2016-02-29 | $59.51M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $28.91M derived: sum of 2 quarters · filed 2016-02-29 | $43.62M derived: sum of 3 quarters · filed 2016-02-29 | $54.88M 10-K · filed 2016-02-29 | $54.88M 10-K · filed 2014-03-06 | |||
| 2013-09-30 | $13.89M 10-Q · filed 2014-11-06 | $13.89M 10-Q · filed 2013-11-14 | $28.60M derived: sum of 2 quarters · filed 2014-11-06 | $39.85M 10-Q · filed 2014-11-06 | $39.86M 10-Q · filed 2013-11-14 | $49.31M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $14.71M 10-Q · filed 2014-08-07 | $14.71M 10-Q · filed 2013-08-13 | $25.97M 10-Q · filed 2014-08-07 | $25.97M 10-Q · filed 2013-08-13 | $35.42M derived: sum of 3 quarters · filed 2015-03-02 | $45.89M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $11.26M 10-Q · filed 2014-05-06 | $20.71M derived: sum of 2 quarters · filed 2015-03-02 | $31.17M derived: sum of 3 quarters · filed 2015-03-02 | $43.09M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $19.92M derived: sum of 2 quarters · filed 2015-03-02 | $31.84M derived: sum of 3 quarters · filed 2015-03-02 | $46.14M 10-K · filed 2015-03-02 | $46.14M 10-K · filed 2014-03-06 | |||
| 2012-09-30 | $10.47M 10-Q · filed 2013-11-14 | $22.39M derived: sum of 2 quarters · filed 2013-11-14 | $36.69M 10-Q · filed 2013-11-14 | |||||
| 2012-06-30 | $11.92M 10-Q · filed 2013-08-13 | $26.22M 10-Q · filed 2013-08-13 | ||||||
| 2011-12-31 | $58.68M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |